NCT04991805View on ClinicalTrials.gov

Descriptive Study of the Incidence of Malignancy in Severe Asthma Patients Receiving Benralizumab and Other Biologic Therapy, a Post Authorization Safety Study

CompletedOBSERVATIONAL

Enrollment

14,000

Participants

Timeline

Start Date

February 26, 2021

Primary Completion Date

April 5, 2024

Study Completion Date

April 5, 2024

Conditions

AsthmaNeoplasms

Trial Locations (2)

128 61

Research Site, Stockholm

NR11 6UN

Research Site, Norwich

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY